Epygenix Therapeutics invites children with Dravet syndrome to participate in a Phase II Clinical Trial
In a Phase II, multicenter, randomized, double-blind, placebo-controlled study Epygenix will test the investigational drug, EPX-100 (Clemizole Hydrochloride, oral solution), as an adjunctive therapy for children with Dravet syndrome (2-17 years old) who suffer from uncontrolled seizures. The trial will take place at investigational sites in the U.S.
The study goal is to compare EPX-100 efficacy versus placebo (measured by percent change in seizure frequency).
To participate, your child would need to meet eligibility criteria. At a minimum, these criteria include:
- Clinical and genetic diagnosis of Dravet syndrome
- Seizure not adequately controlled by current anti-epileptic drugs
- Experience 4 or more convulsive seizure during a 4-week baseline period
Your child’s personal data will remain private and confidential. Any medical data collected in the study will be used exclusively for therapy development. Our aim is to develop transformative therapies to improve the lives of patients and families living with Dravet syndrome.
More information on the trial and trial locations can be found here.